Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
NOVARTIND.NSthis companyEvonile Pharma Limited	₹1,909.10	26.5×	3.02×	6.97×	19.18×	-27.9%	37.5%	26.0%	26.3%	11.4%	7.9%	3.4%	0×	-7.06×	73.13×	5.3×	2.5%	3	—	2	C+
AARTIDRUGS.NSAarti Drugs Limited	₹499.75	14.97×	1.88×	1.14×	11.19×	-76.9%	29.2%	9.4%	7.6%	12.6%	10.1%	1.7%	0.37×	1.82×	7.19×	1.59×	0.6%	4	3.46	2	C
AARTIPHARM.NSAarti Pharmalabs Limited	₹921.40	32.96×	2.71×	3.16×	16.93×	-152.7%	54.1%	16.4%	9.6%	8.2%	7.3%	-3.2%	0.36×	1.94×	6.36×	1.49×	0.6%	6	4.24	3	B-
ASTRAZEN.NSAstraZeneca Pharma India Limited	₹6,529.00	103.53×	22.24×	8.53×	66.87×	74.4%	26.5%	10.3%	8.2%	21.5%	17.0%	0.0%	0.13×	-1.18×	51.99×	1.77×	0.4%	3	—	2	C+
BLISSGVS.NSBliss GVS Pharma Limited	₹654.75	18.76×	2.03×	2.61×	10.25×	-99.6%	54.2%	14.1%	13.9%	10.8%	7.3%	3.4%	0.02×	-0.06×	10.87×	4.02×	0.4%	6	17.76	3	B
CIPLA.NSCipla Limited	₹1,403.80	25.49×	2.87×	3.51×	15.19×	112.4%	42.7%	16.7%	13.8%	11.3%	9.8%	2.6%	0.02×	-0.06×	86.67×	3.44×	1.3%	4	9.92	4	A-
Peer median	—	25.49×	2.71×	3.16×	15.19×	-76.9%	42.7%	14.1%	9.6%	11.3%	9.8%	1.7%	0.13×	-0.06×	10.87×	1.77×	0.6%	4	7.08	3	—